Table 1.
Non-Nerve- Sparing |
Nerve-Sparing Study Cohort |
p-Value | ||||
---|---|---|---|---|---|---|
# | % | # | % | |||
n | 205 | 135 | ||||
Age, yrs | Median (IQR) | 34 | (27, 41) | 30 | (24,35) | <0.001 |
Laterality | Left | 87 | (42%) | 81 | (60%) | 0.001 |
Right | 112 | (55%) | 54 | (40%) | ||
Bilateral | 1 | (0%) | 0 | (0%) | ||
Extragonadal Disease | 5 | (3%) | 0 | (0%) | ||
Clinical Stage | l | 14 | (7%) | 10 | (7%) | <0.001 |
lS | 3 | (1%) | 3 | (2%) | ||
lla | 14 | (7%) | 31 | (23%) | ||
llb | 48 | (23%) | 40 | (30%) | ||
llc | 47 | (23%) | 20 | (15%) | ||
lll | 79 | (39%) | 31 | (23%) | ||
IGCCCG Risk | Good | 131 | (64%) | 113 | (84%) | 0.001 |
Intermediate | 35 | (17%) | 15 | (11%) | ||
Poor | 38 | (19%) | 7 | (5%) | ||
Missing | 1 | (0%) | 0 | (0%) | ||
Chemo Intent | Induction | 193 | (94%) | 126 | (93%) | 0.96 |
Relapse | 11 | (5%) | 7 | (5%) | ||
Missing | 1 | (1%) | 2 | (2%) | ||
Chemo Regimen | BEP | 93 | (45%) | 28 | (21%) | <0.001 |
EP | 108 | (53%) | 107 | (79%) | ||
Other | 4 | (2%) | 0 | (0%) | ||
2nd Line Chemo | 37 | (18%) | 7 | (5%) | 0.001 | |
Elevated Marker | 42 | (20%) | 7 | (5%) | <0.001 | |
PC-RP Nodal Size | <2cm | 88 | (43%) | 104 | (77%) | |
2–5cm | 54 | (26%) | 22 | (16%) | ||
>5cm | 54 | (26%) | 9 | (7%) | ||
missing | 9 | (4%) | 0 | (0%) | ||
Template | Bilateral With | 138 | (67%) | 36 | (27%) | 0.001 |
Contralateral Iliacs | ||||||
Bilateral Without | 54 | (26%) | 99 | (73%) | ||
Contralateral Iliacs | ||||||
Other | 12 | (6%) | 0 | (0%) | ||
Missing | 1 | (1%) | ||||
Number of Nodes | Median (IQR) | 25 | (20, 40) | 27 | (19,39) | 0.083 |
Pathology | Fibrosis/Necrosis | 100 | (49%) | 82 | (61%) | <0.001 |
Teratoma | 80 | (39%) | 53 | (39%) | ||
Viable Germ Cell | 25 | (12%) | 0 | (0%) |
IQR: interquartile range, IGCCCG: International Germ Cell Cancer Collaborative Group, RP: retroperitoneal, PC-RPLND: post-chemotherapy retroperitoneal lymph node dissection